Cytokinetics, Incorporated (NASDAQ:CYTK) shareholders were met with a rude awakening when the firm’s lead ALS asset failed to meet the primary endpoint in its Phase III program, leading to the discontinued development of tirasemtiv. However, Cantor analyst Mara Goldstein has not stepped to the sidelines just yet.
Story Continues
